Recent Price Movement and Market Context
On 02-Feb, Glenmark Pharmaceuticals closed at ₹1,937.40, down by ₹1.95 or 0.1%. This slight fall comes after two consecutive days of losses, during which the stock declined by nearly 3.94%. The intraday low touched ₹1,842.80, marking a 4.98% drop from recent highs. Notably, the weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting some selling pressure during the session.
The stock’s performance over the past week and month has been weaker relative to the benchmark Sensex. While the Sensex gained 0.16% in the last week, Glenmark’s shares fell by 1.69%. Over the past month, the stock declined 6.45%, underperforming the Sensex’s 4.78% drop. Year-to-date, the stock is down 4.84%, slightly worse than the Sensex’s 4.17% fall. These short-term movements contrast sharply with the company’s stellar long-term returns, where it has outpaced the Sensex by a wide margin, delivering 34.83% returns over one year and an extraordinary 397.73% over three years.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Technical Indicators and Trading Activity
From a technical standpoint, Glenmark’s share price remains above its 200-day moving average, a positive long-term signal. However, it is trading below its 5-day, 20-day, 50-day, and 100-day moving averages, indicating short- to medium-term weakness. This divergence suggests that while the stock’s long-term trend remains intact, recent momentum has slowed.
Investor participation has been rising, with delivery volumes on 30 Jan reaching 2.61 lakh shares, a 4.01% increase over the five-day average. This heightened activity, combined with sufficient liquidity to support trades worth approximately ₹1.71 crore, indicates that the stock remains actively traded despite recent price softness.
Fundamental Strengths Supporting the Stock
Despite the recent dip, Glenmark Pharmaceuticals boasts robust fundamentals that underpin its valuation. The company’s ability to service debt is strong, with a low Debt to EBITDA ratio of 0.89 times, signalling prudent financial management. Its latest six-month results reveal net sales of ₹9,947.49 crore, reflecting a substantial growth rate of 45.83%. Profit after tax (PAT) for the same period stands at ₹2,026.77 crore, underscoring significant profitability.
Return on capital employed (ROCE) for the half-year is an impressive 35.65%, while return on equity (ROE) is 23.5%. These metrics highlight efficient capital utilisation and attractive returns for shareholders. The stock’s price-to-book value ratio of 5.7 suggests it is trading at a discount relative to its peers’ historical valuations, offering potential value for investors.
Over the past year, Glenmark’s profits have surged by 890.4%, a remarkable growth that has translated into a 34.83% share price appreciation. The company’s PEG ratio stands at zero, indicating that earnings growth is not yet fully reflected in the stock price, which may appeal to growth-oriented investors.
Institutional investors hold a significant 39.33% stake in the company, reflecting confidence from well-resourced market participants who typically conduct thorough fundamental analysis. Additionally, Glenmark is ranked among the top 1% of companies rated by MarketsMojo across a universe of 4,000 stocks, further validating its strong market position.
Curious about Glenmark Pharma from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Balancing Short-Term Volatility with Long-Term Potential
The recent price decline in Glenmark Pharmaceuticals shares appears to be a short-term correction within a broader context of strong fundamentals and consistent outperformance. While the stock has underperformed the benchmark indices over the past month and week, its long-term returns remain exceptional, with a nearly fourfold gain over three years compared to the Sensex’s 36.26% rise.
Investors should note that the stock’s current valuation discounts some of its growth prospects, as reflected in its attractive price-to-book ratio and low PEG ratio. The company’s solid financial health, demonstrated by its ability to manage debt and deliver high returns on capital, supports a positive outlook. Moreover, the rising institutional interest and active trading volumes suggest that market participants continue to recognise Glenmark’s potential despite recent volatility.
In summary, Glenmark Pharmaceuticals’ slight price fall on 02-Feb is more indicative of short-term market fluctuations rather than a fundamental shift. The company’s strong earnings growth, robust balance sheet, and consistent long-term performance provide a compelling case for investors to consider the stock as a valuable addition to their portfolios.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
